急性肾损伤危重症患者区域枸橼酸抗凝连续性肾脏替代治疗中枸橼酸蓄积影响因素分析
该回顾性病例对照研究纳入2023年1月至2024年12月四川省人民医院ICU接受RCA-CRRT≥24小时的急性肾损伤患者192例、393个循环,按总钙/离子钙比值≥2.5定义枸橼酸蓄积,蓄积组134个循环(34.1%)。多因素Cox回归显示CVVHD模式(HR=2.329,95%CI 1.396-3.884)、总胆红素升高(HR=1.004,95%CI 1.002-1.006)、枸橼酸剂量较高(HR=1.001,95%CI 1.000-1.001)和血乳酸升高(HR=1.091,95%CI 1.036-1.148)为枸橼酸蓄积的危险因素,PaO2升高为保护因素(HR=0.990,95%CI 0.900-1.008,P<0.05)。累积风险曲线显示CVVHD模式枸橼酸蓄积发生率显著高于CVVHDF模式(P=0.001)。结论提示高总胆红素、高枸橼酸剂量、高乳酸和低PaO2与RCA-CRRT期间枸橼酸蓄积风险增加相关,CVVHDF模式较CVVHD模式蓄积风险更低。
要点
- 192例AKI患者393个RCA-CRRT循环中枸橼酸蓄积发生134个(34.1%),蓄积定义为总钙/离子钙比值≥2.5。
- 多因素Cox回归:CVVHD模式较CVVHDF蓄积风险升高(HR=2.329,95%CI 1.396-3.884)。
- 总胆红素升高(HR=1.004,95%CI 1.002-1.006)、枸橼酸剂量较高(HR=1.001,95%CI 1.000-1.001)、血乳酸升高(HR=1.091,95%CI 1.036-1.148)为蓄积危险因素。
- PaO2升高为保护因素(HR=0.990,95%CI 0.900-1.008,P<0.05)。
- 累积风险曲线显示CVVHD模式枸橼酸蓄积发生率显著高于CVVHDF模式(P=0.001)。
适用人群与场景
- 2023年1月至2024年12月四川省人民医院ICU接受RCA-CRRT≥24小时的急性肾损伤患者,共192例、393个循环。
诊断标准与关键阈值
- 枸橼酸蓄积定义:总钙/离子钙比值≥2.5为蓄积组,<2.5为非蓄积组。
研究设计与关键结果
- 回顾性病例对照研究,纳入192例AKI患者393个RCA-CRRT循环,枸橼酸蓄积发生134个循环(34.1%)。
- 单因素Cox分析:治疗模式、总胆红素、枸橼酸剂量、血乳酸、PaO2、置换液剂量、治疗剂量和SOFA评分为潜在影响因素(均P<0.1)。
- 多因素Cox回归:CVVHD模式(HR=2.329,95%CI 1.396-3.884)、总胆红素升高(HR=1.004,95%CI 1.002-1.006)、枸橼酸剂量较高(HR=1.001,95%CI 1.000-1.001)、血乳酸升高(HR=1.091,95%CI 1.036-1.148)为危险因素(均P<0.05)。
- PaO2升高为保护因素(HR=0.990,95%CI 0.900-1.008,P<0.05)。
- 累积风险曲线显示CVVHD模式枸橼酸蓄积发生率显著高于CVVHDF模式(P=0.001)。
证据类型、等级与局限
- 证据类型:回顾性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,较高的总胆红素、较高的枸橼酸剂量、较高的乳酸和较低的PaO2与RCA-CRRT期间枸橼酸蓄积风险增加相关。
- 作者认为,与CVVHD模式相比,CVVHDF模式在接受RCA-CRRT的患者中枸橼酸蓄积风险更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the influencing factors of citrate accumulation in critically ill patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy with regional citrate anticoagulation (RCA-CRRT).
METHODS: A retrospective case-control study was conducted, enrolling AKI patients who received RCA-CRRT for ≥24 hours in the intensive care unit (ICU) of Sichuan Provincial People's Hospital from January 2023 to December 2024 as research subjects. Clinical data were collected, including gender, age, Sequential Organ Failure Assessment (SOFA) before RCA-CRRT initiation, mean blood lactic acid level, mean total bilirubin level from the start of RCA-CRRT to the occurrence of citrate accumulation, mean infusion dose of sodium citrate, mean partial pressure of arterial oxygen (PaO2), mean hourly volume of replacement or dialysate fluid, treatment dose, blood flow rate, treatment mode, and the occurrence of citrate accumulation during RCA-CRRT. Patients were divided into two groups based on the total calcium/ionized calcium ratio: a citrate accumulation group (≥2.5) and a non-citrate accumulation group (<2.5). Baseline data were compared between the two groups. Univariate and multivariate Cox proportional hazards regression analyses were used to screen the influencing factors of citrate accumulation. Cumulative risk curves of citrate accumulation were plotted to analyze the risk of citrate accumulation in different treatment modes [continuous veno-venous hemodialysis (CVVHD) vs. continuous veno-venous hemodiafiltration (CVVHDF)].
RESULTS: A total of 192 AKI patients were enrolled, with 393 circuits of RCA-CRRT treatment, among which citrate accumulation occurred in 134 circuits (34.1%). Univariate Cox proportional hazards analysis showed that treatment mode, total bilirubin level, sodium citrate dose, blood lactic acid level, PaO2, replacement fluid dose, treatment dose and SOFA score were potential influencing factors for citrate accumulation in AKI patients undergoing RCA-CRRT (all P<0.1). Multivariate Cox proportional hazards regression analysis revealed that CVVHD treatment mode [hazard ratio (HR)=2.329, 95% confidence interval (95%CI) was 1.396-3.884], elevated total bilirubin level (HR=1.004, 95%CI was 1.002-1.006), higher citrate dose (HR=1.001, 95%CI was 1.000-1.001) and elevated blood lactic acid level (HR=1.091, 95%CI was 1.036-1.148) were risk factors for citrate accumulation (all P<0.05), while elevated PaO2 was a protective factor (HR=0.990, 95%CI was 0.900-1.008, P<0.05). The cumulative risk curve of citrate accumulation indicated that the incidence of citrate accumulation in the CVVHD mode was significantly higher than that in the CVVHDF mode (P=0.001).
CONCLUSIONS: Higher total bilirubin, higher sodium citrate dose, higher lactate, and lower PaO2 are associated with an increased risk of citrate accumulation during RCA-CRRT. Compared with the CVVHD mode, the CVVHDF mode confers a lower risk of citrate accumulation in patients undergoing RCA-CRRT.
参考来源
- Chen Z, Tang Q, Xie C, et al. [Analysis of influencing factors for citrate accumulation in critically ill patients with acute kidney injury undergoing continuous renal replacement therapy with regional citrate anticoagulation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 41958128. doi:10.3760/cma.j.cn121430-20250623-00347
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。